Multiple-Ascending Dose Study in Healthy Subjects to Assess the Pharmacokinetics, Tolerability, and CYP3A4 Interaction Potential of the T-Type Calcium Channel Blocker ACT-709478, A Potential New Antiepileptic Drug-Reference-Cited by-同舟云学术

Multiple-Ascending Dose Study in Healthy Subjects to Assess the Pharmacokinetics, Tolerability, and CYP3A4 Interaction Potential of the T-Type Calcium Channel Blocker ACT-709478, A Potential New Antiepileptic Drug

Published:2020-01-28 Issue:3 Volume:34 Page:311-323
ISSN:1172-7047
Container-title:CNS Drugs
language:en
Short-container-title:CNS Drugs

Author:

Richard Muriel^ORCID,Kaufmann Priska^ORCID,Ort Marion^ORCID,Kornberger Rüdiger,Dingemanse Jasper^ORCID

Funder

Actelion Pharmaceuticals

Idorsia Pharmaceuticals

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Psychiatry and Mental health,Clinical Neurology

Link

https://link.springer.com/content/pdf/10.1007/s40263-019-00697-1.pdf

Reference35 articles.

1. Behr C, Goltzene MA, Kosmalski G, Hirsch E, Ryvlin P. Epidemiology of epilepsy. Rev Neurol (Paris). 2016;172(1):27–36.

2. Jallon P, Latour P. Epidemiology of idiopathic generalized epilepsies. Epilepsia. 2005;46(Suppl. 9):10–4.

3. Szaflarski JP, Lindsell CJ, Zakaria T, Banks C, Privitera MD. Seizure control in patients with idiopathic generalized epilepsies: eEG determinants of medication response. Epilepsy Behav. 2010;17(4):525–30.

4. Kwan P, Schachter SC, Brodie MJ. Drug-resistant epilepsy. N Engl J Med. 2011;365(10):919–26.

5. Ventola CL. Epilepsy management: newer agents, unmet needs, and future treatment strategies. PT. 2014;39(11):776–92.

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Value of Assessing 1‐Hydroxymidazolam in Drug‐Drug Interaction Studies with Midazolam as a Substrate of Cytochrome P450 3A;The Journal of Clinical Pharmacology;2024-05-26

2. Effect of Daridorexant on the Pharmacokinetics of Midazolam, and on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Male Subjects;Drugs in R&D;2024-03

3. Modeling time‐delayed concentration‐QT effects with ACT‐1014‐6470, a novel oral complement factor 5a receptor 1 (C5a₁ receptor) antagonist;Pharmacology Research & Perspectives;2023-07-20

4. Evaluation of the cytochrome P450 2C19 and 3A4 inhibition potential of the complement factor 5a receptor 1 antagonist ACT‐1014‐6470 in vitro and in vivo;Clinical and Translational Science;2023-04-26

5. Advances in Epilepsy: Mechanisms, Clinical Trials, and Drug Therapies;Journal of Medicinal Chemistry;2023-04-04